Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia

AIDS

Volumn 16, Issue 2, 2002, Pages 201-207

  Deeks, Steven G ^a   Barbour, Jason D ^a,b   Grant, Robert M ^a,b   Martin, Jeffrey N ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

Author keywords

CD4; Combination therapy; HIV drug resistance; Natural history

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE; TREATMENT FAILURE; VIREMIA; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; NELFINAVIR; RITONAVIR; RNA, VIRAL; SAQUINAVIR; TIME FACTORS; TREATMENT FAILURE; VIREMIA;

EID: 0037169269     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201250-00009     Document Type: Article

References (12)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
2. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
3. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
4. Sustained CD4 T cell response after virologic failure of protease inhibitor based regimens in HIV infected patients
5. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
6. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit
7. 1997 revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV)
8. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus - Infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359
9. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
10. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia
11. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure